

66. (Amended) An isolated polynucleotide comprising the complement of a polynucleotide of any one of claims 61-62 or 69, wherein the polynucleotide can be used in the detection of lung cancer.

67. (Amended) An expression vector comprising a polynucleotide according to any one of claims 61-62 or 69.

Please add new claim 69 to read as follows:

69. (New) An isolated polynucleotide comprising at least 175 contiguous residues of the polynucleotide sequence of SEQ ID NO:808.

#### REMARKS

Favorable reconsideration of the subject application is respectfully requested in view of the following remarks. By this amendment, claims 1-3, 11-60, and 63-65 are cancelled. New claim 69 has been added to more clearly recite one aspect of the originally claimed invention. Claims 62, 66, and 67 have been amended to more clearly recite the claimed subject matter. Support for the amendment may be found throughout the claims and specification as originally filed. Support for isolated polynucleotides comprising at least 175 nucleotides of SEQ ID NO:808 is provided, *e.g.*, on page 67, lines 6-12. This amendment is not to be construed as acquiescence to any rejection and is made without prejudice to prosecution of any subject matter modified by the amendment in a related divisional, continuation, or continuation-in-part application.

The Applicants wish to thank the Examiner for meeting with Applicants' representatives to interview this case. Applicants appreciate the Examiner's careful consideration of the claimed subject matter and his helpful discussion regarding allowable subject matter. Applicants believe that the claims, as presently amended, are allowable in light of this discussion and the remarks set forth below.